300 related articles for article (PubMed ID: 11390552)
1. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses.
Maurea S; Klain M; Mainolfi C; Ziviello M; Salvatore M
J Nucl Med; 2001 Jun; 42(6):884-92. PubMed ID: 11390552
[TBL] [Abstract][Full Text] [Related]
2. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques.
Maurea S; Caracò C; Klain M; Mainolfi C; Salvatore M
Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):188-97. PubMed ID: 15499292
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of radionuclide imaging using 131I nor-cholesterol or meta-iodobenzylguanidine in patients with hypersecreting or non-hypersecreting adrenal tumours.
Maurea S; Klain M; Caraco C; Ziviello M; Salvatore M
Nucl Med Commun; 2002 Oct; 23(10):951-60. PubMed ID: 12352593
[TBL] [Abstract][Full Text] [Related]
4. Quantitative imaging characterization of hypersecreting or nonhypersecreting adrenal adenomas: comparison between iodine-131 norcholesterol uptake and magnetic resonance signal intensity ratios.
Maurea S; Imbriaco M; Mollica C; Pace L; Salvatore M
Nucl Med Commun; 2011 Jun; 32(6):535-41. PubMed ID: 21448089
[TBL] [Abstract][Full Text] [Related]
5. Role of molecular imaging in management of nonhypersecreting adrenal masses.
Lawson MA
J Nucl Med; 2001 Jun; 42(6):893-4. PubMed ID: 11390553
[No Abstract] [Full Text] [Related]
6. The value of 18F-FDG PET-CT and 131I-norcholesterol scintigraphy in the characterization of high-risk adrenal masses.
Riaz S; Syed R; Aziz TA; Alnaim A; Chung TT; Wan S; Kurzawinski TR; Bomanji J
Nucl Med Commun; 2020 Mar; 41(3):189-195. PubMed ID: 31895761
[TBL] [Abstract][Full Text] [Related]
7. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
Boland GW; Blake MA; Holalkere NS; Hahn PF
AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT in the evaluation of adrenal masses.
Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E
J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184
[TBL] [Abstract][Full Text] [Related]
9. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
[TBL] [Abstract][Full Text] [Related]
11. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
[TBL] [Abstract][Full Text] [Related]
12. [Positron emission tomography (PET) with fludeoxyglucose F 18 in the study of adrenal masses: comparison of benign and malignant lesions].
Maurea S; Mainolfi C; Wang H; Varrella P; Panico MR; Klain M; Rossi R; Cremona F; Bazzicalupo L; Salvatore M
Radiol Med; 1996 Dec; 92(6):782-7. PubMed ID: 9122472
[TBL] [Abstract][Full Text] [Related]
13. A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma.
Cecchin D; Lumachi F; Marzola MC; Opocher G; Scaroni C; Zucchetta P; Mantero F; Bui F
Endocr Relat Cancer; 2006 Jun; 13(2):525-33. PubMed ID: 16728579
[TBL] [Abstract][Full Text] [Related]
14. [Adrenal incidentaloma and nuclear medicine examination].
Tenenbaum F
J Radiol; 2009 Mar; 90(3 Pt 2):444-8. PubMed ID: 19421135
[TBL] [Abstract][Full Text] [Related]
15. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG.
Minn H; Salonen A; Friberg J; Roivainen A; Viljanen T; Långsjö J; Salmi J; Välimäki M; Någren K; Nuutila P
J Nucl Med; 2004 Jun; 45(6):972-9. PubMed ID: 15181132
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of chemical-shift MR imaging to differentiate between adrenal adenomas and non adenoma adrenal lesions.
Maurea S; Imbriaco M; D'Angelillo M; Mollica C; Camera L; Salvatore M
Radiol Med; 2006 Aug; 111(5):674-86. PubMed ID: 16791464
[TBL] [Abstract][Full Text] [Related]
17. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
Mann GN; Link JM; Pham P; Pickett CA; Byrd DR; Kinahan PE; Krohn KA; Mankoff DA
Ann Surg Oncol; 2006 Feb; 13(2):187-97. PubMed ID: 16418883
[TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of norcholesterol scintigraphy, CT attenuation value, and chemical-shift MR imaging for characterizing adrenal adenomas.
Yoh T; Hosono M; Komeya Y; Im SW; Ashikaga R; Shimono T; Tsuchiya N; Okada M; Hanada K; Yagyu Y; Nishimura Y; Murakami T
Ann Nucl Med; 2008 Jul; 22(6):513-9. PubMed ID: 18670858
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the large adrenal mass.
Khafagi FA; Gross MD; Shapiro B; Glazer GM; Francis I; Thompson NW
Br J Surg; 1991 Jul; 78(7):828-33. PubMed ID: 1873713
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
Lu Y; Xie D; Huang W; Gong H; Yu J
Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
